Board of Directors

Ivan Coulter, B.Sc., PhD, MBA, Chief Executive Officer, Director and Founder

Dr. Coulter has built a reputation for innovation and leadership since founding Sigmoid in 2003, and developing its lead technology and products. Prior to Sigmoid, Dr. Coulter set up, developed and managed the drug formulation and diagnostics groups at NTera, a nanotechnology-focused company. Dr. Coulter has an honours degree and PhD in Pharmacology from University College Dublin, held a Post-Doctoral Fellowship at the Institut Curie, Paris, holds a Diploma in Accounting and Finance awarded by the Association of Chartered and Certified Accountants (ACCA) and was awarded a Fulbright Scholarship to complete an MBA at Cornell University, New York. Dr. Coulter is a member of the Irish Research Council.

Thomas G. Lynch, Chairman

Tom Lynch began his career as an accountant becoming partner at KPMG in 1990. He founded the firm that became contraceptives maker Warner Chilcott in 1994. He held senior roles at Elan, including CFO and executive vice-president from 1993-2002 and senior adviser from 2002 to 2004. He was chairman at NASDAQ-listed Amarin from 2000 to 2011, and CEO from 2007 to 2011.. Tom serves on a number of private for-profit and not-for-profit boards, including serving as Chair of Adherium Limited, Evofem Biosciences Inc., Profectus Biosciences Inc., Ireland East Hospitals Group and is Chair of the Queen'ss University Belfast Foundation and HRH the Prince of Wales' Foundation for Integrated Health. He is an economics graduate from Queen’s University Belfast.

Alan McShane MB, BSc, FRCPI, FFARCSI, (Non-executive Director)

Dr McShane is a graduate of University College Dublin (UCD), having received his medical degree in 1976. He carried out extensive laboratory and clinical research, both at UCD and at the John Hopkins University Hospital, Baltimore, Maryland. Alan returned to Ireland in 1987 when he was appointed as a consultant anaesthetist at St. Vincent’s Hospital, Dublin. At St. Vincent’s, Alan has held a number of key management roles, including Director of the Intensive Care Unit.

Roderick Ryan, B. Comm, FCA, AITI (Non-executive Director)

Mr. Ryan is a former Managing Partner of Arthur Andersen in Ireland and has an extensive knowledge of financial reporting, corporate taxation, governance and regulatory developments

Mr. Ryan is a non-executive director of Glen Dimplex and other companies and Senior Independent Director of Grafton Group plc. He is a member of the Chartered Accountants Regulatory Board. He formerly served as a member of the Government-appointed IFSC Banking and Treasury Committee and the Revenue Powers Group and as Chairman of the Foundation for Fiscal Studies

Michael D. Parker, CBE, MBA, BSc (Non-executive Director)

Mr. Parker brings a wealth of experience to Sigmoid, with 34 years at The Dow Chemical Company, where he was President and CEO from 2000 to 2002, and where he had a number of previous leadership roles in research, manufacturing and commercial in the USA, UK, Switzerland and Hong Kong. He served as CEO at British Nuclear Fuels PLC (BNFL) from 2005 to 2009

Mr Parker has served as Chairman of Bng America LLC and of the National Nuclear Laboratory Limited. He holds a number of Director roles including at PV Crystalox Solar plc, Tianhe Chemicals plc and SNC-Lavalin Group Inc.

Mr. Parker has a Bachelor's degree in Chemical Engineering from the University of Manchester and MBA from the Manchester Business School

David Goodman, PhD(Non-executive Director)

Dr. Goodman is Chief Executive Officer of Pharmascience Inc., a Canadian fully-integrated pharmaceutical company involved in the development, manufacture and distribution of a broad line of generic and branded products. Under Dr. Goodman’s leadership, Pharmascience has grown to become a top ten Canadian Pharmaceutical company, the third largest pharmaceutical company in Canada by number of prescriptions with a diversified portfolio of over 340 product families and sales in more than 60 countries. David obtained his Bachelor of Commerce degree from McGill and a Ph.D. in pharmacology from the University of Virginia. He began his career at Pharmascience in Business Development and prior to being appointed CEO he was Executive Vice President, Pharmascience International.

Lorin K. Johnston, PhD - (Non-executive Director)

Dr. Johnson is the founder and Chief Scientist of Glycyx PharmaVentures Ltd. He co-founded Salix Pharmaceuticals, Inc. (NASDAQ: SLXP) and held senior leadership positions prior to its $15.8 billion acquisition by Valeant Pharmaceuticals International, Inc. (NYSEA: VRX). Prior to Salix, Dr. Johnson served as Director of Scientific Operations and Chief Scientist at Scios, Inc. (Formerly, California Biotechnology, Inc). He is a Director of Atlantic Healthcare plc. In addition to his career in industry, Dr. Johnson has served as an Assistant Professor of Pathology at Stanford University Medical Center and held academic positions at Stanford University School of Medicine and the University of California, San Francisco. He is the co-author of 75 journal articles and book chapters and is the co-inventor on 18 issued patents. Dr. Johnson holds a PhD from the University of Southern California and was a Postdoctoral Fellow at the University of California, San Francisco.

Alan Kane, Company Secretary

Alan Kane has support Sigmoid in a number of roles since 2007 including as member of the Board of Directors, Finance Director, and most recently as Company Secretary. He is also Managing Director of Sentinel Investments (Shannon) Limited, a privately owned Irish company, established in June 1988 and licensed by the Irish Government to trade in a wide range of financial services. The core elements of Sentinel’s business are Structured Finance, Company Management Services and Portfolio Management. In the initial phase of his career Alan qualified as a Chartered Secretary and subsequently trained as an accountant with PriceWaterhouse in Dublin.

Senior Management

Ivan Coulter, B.Sc., PhD, MBA, Chief Executive Officer, Director and Founder

Dr. Coulter has built a reputation for innovation and leadership since founding Sigmoid in 2003, and developing its lead technology and products. Prior to Sigmoid, Dr. Coulter set up, developed and managed the drug formulation and diagnostics groups at NTera, a nanotechnology-focused company. Dr. Coulter has an honours degree and PhD in Pharmacology from University College Dublin, held a Post-Doctoral Fellowship at the Institut Curie, Paris, holds a Diploma in Accounting and Finance awarded by the Association of Chartered and Certified Accountants (ACCA) and was awarded a Fulbright Scholarship to complete an MBA at Cornell University, New York. Dr. Coulter is a member of the Irish Research Council.

Leo Toole, Chief Financial Officer

Leo Toole joined Sigmoid in October 2015 with an impressive track record in both private and public companies inmedtech and consumer goods sectors. Since 2011, he has been Finance Director at ResMed Inc. reporting to the Chief Financial Officer. Prior to that, as Chief Financial Officer at BiancaMed, where he was instrumental in fundraising, establishing and growing a robust finance function, and securing a major liquidity event through tradesale to ResMed. Leo spent nearly 10 years in finance with Procter & Gamble, the world’s leading consumer goods company. Leo graduated with Distinction from INSEAD and completed his undergraduate studies in Trinity College Dublin and HEC Liege.

David Roblin, BSc, MBBS, FRCP, MFPM, Chief Medical Advisor

Dr. Roblin’s career, spanning more than 15 years, has seen him deliver several drugs to the market. He has held leadership roles in Pfizer and Bayer. At Pfizer, Dr. Roblin was most recently Senior Vice President, Head of Research and Site Head for R&D. Dr. Roblin is a Fellow of the Royal College of Physicians and Member of the Faculty of Pharmaceutical Physicians. Dr. Roblin has chaired the Research Director’s Group of the European Federation of Pharmaceutical Industries and Associations (EFPIA), and was a co-founder of the Innovative Medicines Initiative, a $2bn public-private partnership with the European Commission. He is currently an advisor to NOCRI in the NHS.

Rosemarie Tully, BSc (Pharm), MBA, MPSI, Chief Business Officer

Rosemarie joined Sigmoid in late 2011 bringing more than 14 years’ experience in business development, strategy and project management. Most recently, from 2008 – 2011, Rosemarie was Senior Director, Corporate Development at Elan Corporation, plc, involved in a number of major corporate transactions. Prior to that, she held a number of roles in the drug delivery division of Elan, the corporate development group in New York and the launch team for Tysabri®. Rosemarie also worked as a management consultant with McKinsey & Company. Rosemarie is a Member of the Pharmaceutical Society of Ireland, completed her B.Sc. (Pharm) degree at Trinity College, Dublin, Ireland and her MBA at INSEAD, France.

 

Sigmoid Pharma , The Invent Centre
Dublin City University, Dublin 9, Ireland